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ABSTRACT
The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) 
circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is 
strongly associated with poor prognosis. This raises the question about the presence 
and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In 
the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow 
CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. 
Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic 
breast cancer patients were processed at six participating sites, using protocols and 
tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had 
≥5 EpCAMhigh CTC and 28% had ≥5 EpCAMlow CTC. For breast cancer patients, 32% had 
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≥5 EpCAMhigh CTC and 36% had ≥5 EpCAMlow CTC. 70% of prostate cancer patients 
and 64% of breast cancer patients had in total ≥5 EpCAMhigh and/or EpCAMlow CTC, 
increasing the number of patients in whom CTC are detected. Castration-resistant 
prostate cancer patients with ≥5 EpCAMhigh CTC had shorter overall survival versus 
those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had 
no relation with overall survival. This emphasizes the importance to demonstrate 
the relation with clinical outcome when presence of CTC  identified with different 
technologies are reported, as different CTC subpopulations can have different relations 
with clinical outcome.
INTRODUCTION
The presence of circulating tumor cells (CTC) 
expressing the cell surface epithelial cell adhesion 
molecule (EpCAM) as well as intracellular cytokeratins 
(CK), are associated with poor outcome in patients with 
metastatic as well as non-metastatic disease [1–8]. In the 
CellSearch® system, CTC that show no or low expression 
of EpCAM are discarded during magnetic isolation and 
their information is lost. This raises the question how many 
of these EpCAM-negative or EpCAM low expressing CTC 
(hereinafter referred to as EpCAMlow CTC) are present and 
whether or not their presence is also associated with poor 
outcome. In the FP7 EU program CTC-Trap (https://www.
utwente.nl/tnw/ctctrap/) this question was investigated by 
collecting the blood discarded by the CellSearch system 
after immunomagnetic enrichment of EpCAMhigh cells. This 
sample is passed through a microfilter and cells remaining 
on the filter were  fluorescently labeled for EpCAMlow 
CTC scoring [9]. To validate this method for detection of 
epithelial EpCAMlow CTC, the procedure was tested at six 
different sites in the CTC-Trap consortium. Healthy donor 
blood spiked with cells of the prostate cancer cell line 
PC3 (1.0 × 104 EpCAM antigens, average size 17.7 µm) 
and the breast cancer cell line MDA-MB-231 (1.5 × 104 
EpCAM antigens, average size 15.6 µm) were tested for 
recovery of EpCAMhigh and EpCAMlow cells. Subsequently, 
the presence of EpCAMhigh and EpCAMlow CTC was 
investigated in 108 CRPC patients and 22 metastatic breast 
and their presence was related to overall survival. 
RESULTS
Validation of CTC detection protocols across 
sites 
On average, 270 PC3 or MDA-MB-231 cells were 
spiked per tube in 36 7.5 mL blood samples of three healthy 
donors and sent to the six sites for processing according 
to the established protocols (Figure 1). The recovery of 
PC3 (median size 17.7 µm) and MDA-MB-231 cells 
(median size 15.6 µm) was determined using CellSearch 
(for EpCAMhigh cells) and on microsieves (for EpCAMlow 
cells), after filtration of the blood discarded by CellSearch. 
The distribution of the EpCAM density is illustrated in 
Supplementary Figure 1. The results are illustrated in 
Figure 2 and a detailed overview of cell recovery per site 
is provided in Supplementary Figure 2. For EpCAMhigh 
CTC detected by CellSearch, the recovery of PC3 cells 
varied between 11.9% and 40.6% (mean 26.9% ± 9 
standard deviation (SD)) and for MDA-MB-231 between 
2.7% and 39.0% (mean 25.7% ± 10 SD). For EpCAMlow 
tumor cells detected on the microsieves after filtration of 
the CellSearch discarded blood, the recovery of PC3 cells 
varied between 0.6% and 42.5% (mean 15.1% ± 11 SD) 
and for MDA-MB-231 between 0% and 29.3% (mean 
12.8% ± 9 SD). In 18 7.5 mL blood samples obtained from 
three healthy donors, who donated together all 54 samples, 
no EpCAMhigh and no EpCAMlow cells were detected. 
EpCAMhigh and EpCAMlow CTC in blood from 
metastatic breast and prostate cancer patients 
EpCAMhigh and EpCAMlow CTC were enumerated 
in 7.5 mL blood obtained from 108 CRPC and 22 mBC 
patients. A detailed overview of the number of CTC 
detected in the patients is provided in Table 1, whereas 
the actual CTC numbers for each patient is listed in 
Supplementary Table 1 and visualized in Supplementary 
Figure 3.  In CRPC patients, EpCAMhigh CTC ranged 
from 0–3300 (median: 6, mean: 124 ± 400 SD) and 
EpCAMlow CTC ranged from 0–24 (median: 1, mean: 3 
± 4 SD). In mBC patients, EpCAMhigh CTC ranged from 
0–208 (median: 1, mean: 13 ± 43 SD) and EpCAMlow 
CTC ranged from 0–35 (median: 3, mean: 3 ± 11 SD). 
In CRPC patients, ≥5 EpCAMhigh CTC or ≥5 EpCAMlow 
CTC were detected in 56 (53%) and 26 (28%) patients, 
respectively. In the group of mBC patients, 7 (32%) 
showed ≥5 EpCAMhigh CTC and 8 (36%) ≥5 EpCAMlow 
CTC. Summing EpCAMhigh CTC and EpCAMlow CTC to 
≥5 CTC, we observed in 70% positive CRPC (n = 91) 
and 64% positive mBC patients, increasing the combined 
CTC-positivity rates by 32% and 100% respectively, in 
comparison to positivity rates for EpCAMhigh CTC only. In 
total, 37% CRPC patients and 23% mBC patients had ≥5 
EpCAMhigh CTC, but <5 EpCAMlow CTC. Vice versa, <5 
EpCAMhigh CTC and ≥5 EpCAMlow CTC were detected in 
10% CRPC and in 18% mBC patients. Figure 3 presents 
a gallery of EpCAMhigh CTC (upper panels 3A–3H) and 
EpCAMlow CTC (lower panels 3I–3P) that were found in 
CRPC patients (left panels 3A–3D and 3I–3L) and mBC 
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patients (right panels 3E–3H and 3M–3P), showing CTC 
of various sizes and staining of CK intensity. 
Overall survival of CRPC patients with 
EpCAMhigh and EpCAMlow CTC 
Follow-up data from patients that were enrolled in 
ongoing clinical trials could not be obtained at the time 
this manuscript was written. Therefore, follow-up data 
could only be obtained from 85 out of 108 CRPC patients 
and 16 out of 22 mBC patients. The cohort of mBC 
patients that remained was too small for survival analysis 
and was therefore omitted. 
To relate the presence of CTC in CRPC patients 
to overall survival, the patient cohort was split into a 
favorable group and an unfavorable group, using 5 CTC as 
Figure 1: Schematic representation of the study. Left panel: one site collected blood from three healthy donors and prepared 
three tubes for each of the six sites (Spike) to send for enumeration of EpCAMhigh cell line CTC (CellSearch) and EpCAMlow cell line CTC 
(Collection EpCAM Depleted Blood and Filtration): no cells were spiked in tube 1, tube 2 was spiked with on average 270 PC3 cells and 
tube 3 was spiked with on average 270 MDA-MB-231 cells. This process was repeated three times with three different healthy donors. 
Right panel: blood samples collected from 108 castrate-resistant prostate cancer patients and 22 metastatic breast cancer patients (Blood 
Draw) at each clinical site were processed for enumeration of EpCAMhigh CTC (CellSearch), followed by detection of EpCAMlow CTC 
(Collection EpCAM Depleted Blood and Filtration). CTC are detected by fluorescence microscopy and scored (Analysis) and the results 
are related to outcome (Statistics).
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a threshold [2, 4]. In Figure 4 the Kaplan-Meier curves for 
EpCAMhigh and EpCAMlow CTC are shown. A significant 
difference is observed for the presence of ≥5 EpCAMhigh 
CTC in relation to overall survival (p = 0.000) (Figure 
4A), whereas no significant difference is observed for ≥5 
EpCAMlow CTC (p = 0.317) (Figure 4B). The combination 
of EpCAMhigh CTC and EpCAMlow CTC was related with 
overall survival by separating the cohort into four groups 
(Supplementary Figure 4A). This shows again that the 
strong correlation with survival can be solely contributed 
to EpCAMhigh CTC and not to EpCAMlow CTC (p = 
0.000). Since ≥5 EpCAMlow CTC show no correlation with 
survival, perhaps a lower CTC cut-off value would show 
a correlation. However, the scatter plot of the number of 
EpCAMlow CTC versus survival of these patients in Figure 
4D shows no trend between these two factors, whereas 
this trend is visible between survival and EpCAMhigh CTC 
(Figure 4C). A receiver operating characteristic (ROC) 
curve was then used to determine the highest diagnostic 
cut-off value for EpCAMlow CTC. Although this calculates 
a threshold at ≥1 EpCAMlow CTC, this value can be 
considered inconclusive since the separation between 
sensitivity and specificity is very low (Supplementary 
Figure 4B). Using the threshold of ≥1 EpCAMlow CTC 
also no relation can be observed with overall survival 
(p = 0.748) (Supplementary Figure 4C).
DISCUSSION
In this multicenter study we determined the presence 
of EpCAMhigh and EpCAMlow CTC in castration resistant 
prostate cancer and metastatic breast cancer patients. 
Protocols and tools for detection were developed in the 
FP7-program CTC-Trap and validated at six clinical 
sites cooperating in the program. The current standard 
CellSearch method for CTC enumeration was used for 
Figure 2: Recovery of PC3 and MDA-MB-231 cancer cells for each clinical site. Recovery of on average 270 PC3 cells and 
MDA-MB-231 cells spiked in each blood sample, processed with the methods for EpCAMhigh and EpCAMlow CTC detection. The samples 
were processed with CellSearch to determine the recovery of EpCAMhigh CTC and the EpCAM depleted blood was filtered through 5 µm 
microsieves to determine the recovery of EpCAMlow cells. In total, per site (labeled #1–6) three samples per cell line and three negative 
controls were processed. The average recovery per three samples is displayed with its standard deviation, followed by an average recovery 
of all sites per method and cell line. 
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the detection of CTC expressing EpCAM, followed by 
capturing and filtering of the sample depleted of these 
EpCAMhigh CTC, and stained for detection of epithelial 
CTC expressing no or low EpCAM (Figure 1). 
To validate the procedure of CellSearch followed by 
filtration for detection of EpCAMlow CTC, samples spiked 
with cells from the PC3 or MDA-MB-231 cancer cell lines 
were used. In the EpCAMhigh CellSearch fraction, 71% of 
Figure 3: Gallery of captured CTC in CRPC and mBC patients. Display of EpCAMhigh CTC (panels A–H) captured with 
CellSearch and EpCAMlow CTC (panels I–P) captured with microsieves in castrate-resistant prostate cancer patients (left panels A–D 
and I–L) and metastatic breast cancer patients (right panels E–H and M–P). Cells in panel (A–B) are from the same patient, as are the 
cells in panels (C–D, E–F, G–H and I–J). The value for intensity of CK staining (green) is represented in the vertical bar next to the 
image, visualizing a very high intensity value with maximum 4095 counts as a full green bar. The nucleus is stained with DAPI (blue). The 
unlabelled scale bar for EpCAMhigh CTC images is 6.4 µm. 
Table 1: Frequency of CTC in CRPC and mBC patients
Prostate cancer Breast cancer
% patients with EpCAMhigh CTC % patients with EpCAMhigh CTC



















0 12.1 9.9 22.0 18.7 44.0 18.2 4.5 9.1 9.1 31.8
1–4 5.5 6.6 15.4 14.3 27.5 9.1 9.1 13.6 4.5 31.8
≥5 7.7 2.2 18.7 16.5 28.6 13.6 13.6 9.1 4.5 36.3
≥10 1.1 0 5.5 4.1 6.6 9.1 9.1 9.1 4.5 27.3
Total 25.3 18.7 56 49.5 100  40.9 27.3 31.8 18.2 100
The frequency (%) of EpCAMhigh and EpCAMlow CTC in 7.5 mL of blood of 91 castration-resistant prostate cancer patients 
and 22 metastatic breast cancer patients.
Oncotarget35710www.oncotarget.com
the PC3 total spiked cells were recovered and 74% of the 
spiked MDA-MB-231 cells. The actual expression levels 
of EpCAM on EpCAM expressing CTC is an important 
question. Rao et al. reported the EpCAM expression on 
100 blood samples of metastatic cancer patients in which 
CTC were detected by flow cytometry and reported an 
Figure 4: Overall survival for CRPC patients. Kaplan–Meier curve of overall survival of patients with EpCAMhigh CTC from 
CellSearch (A), EpCAMlow CTC from microsieves (B) show a strong correlation between EpCAMhigh CTC and survival, but no correlation 
between EpCAMlow CTC and survival. Scatter plot of survival versus the amount of EpCAMhigh CTC (n = 83) visualizes the expected trend 
that most patients with high number of CTC have a short survival (C), whereas the amount EpCAMlow CTC in patients (n = 73) show no 
such trend (D).
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average EpCAM density of 5.0 × 104 EpCAM antigens 
[10]. This density is fivefold higher than that of the PC3 
(on average 1.0 × 104 EpCAM antigens) and MDA-
MB-231 (on average 1.5 × 104 EpCAM antigens) 
cells used in this study. However, these numbers are 
the average density and the actual distribution of the 
EpCAM expression can be quite broad, as illustrated in 
Supplementary Figure 1 [10]. The data supports our notion 
that the majority of CTC with relatively high EpCAM 
antigen density are captured by CellSearch, while CTC 
expressing no EpCAM or low EpCAM levels will be 
present in the EpCAM depleted fraction. After passage of 
the EpCAM depleted blood through microsieves, only a 
portion of the spiked cells –and most likely also CTC – 
will be captured. 
Relative recovery of PC3 cells and MDA-MB-231 
in the EpCAMhigh fraction (CellSearch) and EpCAMlow 
fraction (microsieve), as shown in Figure 2, followed the 
expectations given the size and EpCAM distribution of 
both cell lines. Although in line with previous reports, the 
absolute number recovered cells is relatively low, thereby 
raising the question where and how these cells were lost 
[9, 11]. Only a small part of cells are destroyed during 
the CellSearch procedure, indicated by the 90% recovery 
of cells that express EpCAM at a very high density [9]. 
Therefore, it is likely to assume most are lost before 
measurement or during the filtration process. Some of 
the cells may be missed because they lack sufficient 
immunostaining for detection, or the cells have simply 
been degraded before or during the process, as they were 
not extensively fixed apart from the light fixative used 
during spiking the blood samples.
The observed recovery rates retrieved for each cell 
line includes variation introduced by EpCAM density, 
by different operators at each clinical site and by the 
three measurements for each cell line (Figure 2 and 
Supplementary Figure 2). Clearly, the variation in the 
obtained results vary a lot between the sites, stressing the 
need for standardization and proficiency testing to assure 
accurate reporting of actual CTC numbers. Variation 
introduced by the interpretation of the images of the CTC 
can be eliminated by the recently introduced ACCEPT 
open-source imaging program [12, 13].
In both CRPC and mBC patients, EpCAMhigh and 
EpCAMlow CTC were detected in 7.5 mL blood (Table 1). 
The number of patients with positive detection of CTC can 
be increased when both EpCAMhigh and EpCAMlow CTC 
are used for the ≥5 CTC threshold. This corresponds to our 
previous report of a small pilot study with 28 non-small 
cell lung cancer (NSCLC) patients [9]. Also, these findings 
fit in the trend of recently published filtration based studies, 
which are reporting large amounts of CTC detected when 
compared to CellSearch [6, 14–17]. A biological reason 
for this increase in CTC counts is by many thought to be 
related to epithelial-to-mesenchymal transition (EMT), 
which is accompanied by loss of epithelial markers, such 
as EpCAM and CK, and by an increase of mesenchymal 
markers, such as vimentin. However, co-expression of 
epithelial markers and mesenchymal markers on CTC also 
have been reported  [18–25]. In this study, EpCAMlow CTC 
expressing cytokeratins are detected, leaving the question 
open on the frequency and clinical relevance of  EpCAMlow 
CTC lacking CK and expressing mesenchymal markers 
[21, 22].
To determine whether the presence of EpCAMhigh 
and EpCAMlow CTC had similar clinical relevance in 
CRPC patients, we correlated their presence with the 
time of survival. The threshold of >5 CTC for EpCAMhigh 
is the threshold used in the original metastatic breast 
and prostate studies and was therefore also used for 
EpCAMlow CTC  to distinguish between favorable and 
unfavorable patient groups [3, 23]. Whereas the presence 
of EpCAMhigh CTC strongly related to a poor survival 
(Figure 4A), the presence of EpCAMlow CTC did not 
(Figure 4B). A threshold of ≥1 CTC for EpCAMlow 
CTC also showed no significant relation to survival, as 
illustrated by the ROC curves and Kaplan-Meier curve 
presented in Supplementary Figure 4. Similar observations 
were made in NSCLC and this prompts the question what 
type of cells these EpCAMlow cells truly are [9]. Here, we 
define these cells as having no or low EpCAM expression, 
based on the effective depletion of cells expressing higher 
levels of EpCAM by the CellSearch system and relatively 
low capture of cells expressing low levels of EpCAM 
(Figure 2). The EpCAMlow cells have a nucleus identified 
by DAPI, express CK, but not CD45. The presence of 
CK shows that these cells are of epithelial origin, but do 
not proof that they are indeed tumor cells [24]. The CK 
expression in CTC is variable, even in the same patient 
(Figure 3). EpCAMlow cells that resemble the morphology 
of EpCAMhigh CTC (Figure 3A–3H) have a higher intensity 
and filamentous pattern of CK (Figure 3I, 3J), whereas low 
CK intensity cells show irregular CK expression (Figure 
3K–3P). This may indicate that these cells are different 
subtypes of CTC, where each subpopulation could express 
its own characteristics and clinical behavior [25]. Even 
so, the intensity of CK staining can be very low in some 
patients making it difficult for operators to score CTC. 
Even using clearly defined criteria for operators to follow 
in scoring CTC, the discrepancy between operators can 
be high and argues for an automated approach to analyze 
images for cells of interest [12, 13]. Definitive proof of 
the cancerous nature of the EpCAMlow cells will need to 
come from the genetic analysis of the cells, as well as the 
differences between the genetic and proteomic make-up of 
the EpCAMhigh and EpCAMlow cells. 
Concluding, in this multicenter study we validated 
the detection of EpCAMhigh and EpCAMlow CTC from 
the same blood draw tube using the CellSearch system 
for enumeration of the EpCAMhigh and by microscopic 
examination of EpCAMlow after passage of the blood 
depleted from EpCAMhigh cells through microsieves. 
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We showed that the number of CTC detected in both 
metastatic breast and prostate cancer can be increased 
when considering both EpCAMhigh and EpCAMlow CTC, 
but also show that only the presence of EpCAMhigh CTC, 
and not EpCAMlow CTC, are strongly correlated with 
poor overall survival. This emphasizes the importance 
to demonstrate the relation with clinical outcome when 
presence of CTC  identified with different technologies 
are reported, as different CTC subpopulations can have 
different relations with clinical outcome.
METHODS
Blood samples
Peripheral blood samples were drawn by 
venepuncture into 10 mL CellSave Preservative Tubes 
(Menarini Silicon Biosystems, Huntingdon Valley PA, 
USA) from healthy donors, metastatic breast and castration 
resistant prostate cancer patients. All patients and healthy 
donors provided written informed consent and the study 
protocol was approved by the medical ethical committee’s 
at each participating site. Patient demographics of patients 
with known clinical outcome are provided in Table 2. The 
sites in the CTC-Trap consortium collaborating in this 
validation study are: The Institute of Cancer Research, 
The Royal Marsden Hospital, NHS Foundation Trust 
(ICR), United Kingdom; Institute Gustave Roussy (IGR), 
France, Instituto Oncologico Veneto (IOV), Italy; Ludwig-
Maximilians-University Muenchen (LMU), Germany; 
Universitätsklinikum Düsseldorf (UKD), Germany; and 
the Universiteit Twente (UT), the Netherlands. CRPC 
patients (at sites ICR, IGR and IOV) and metastatic breast 
cancer patients (at sites LMU and UKD) were recruited 
and processed on site within 96 hours. A schematic 
overview of the study is shown in Figure 1.
Cell lines and spiking
Spiking experiments were performed with cells 
from the prostate carcinoma cell line PC3 and the breast 
carcinoma cell line MDA-MB-231. These cell lines were 
chosen for their low expression of EpCAM, which would 
allow us to find a fraction in both the EpCAMhigh and 
EpCAMlow fraction. The median size of the MDA-MB-231 
cells was 15.6 µm with an average EpCAM density of 
1.5 × 104 (165 %CV) antigens. The median size of the PC3 
cells was 17.7 µm with an average EpCAM density of 
1.0 × 104 (89 %CV) antigens. The histograms showing the 
distribution of the EpCAM density of the PC3 and MDA-
MB-231 cells is shown in Supplementary Figure 1. For 
comparison, the EpCAM density of the breast cancer cell 
line MCF-7, expressing EpCAM at much higher density, 
is shown in the figure as well. All cell lines were obtained 
from ATCC (Manassa VA, USA) and have not been 
authenticated in the past four years. They were grown 
at 37° C and 5% CO2. The PC3 cell line was cultured in 
RPMI-1640 (Life Technologies Corporation, Carlsbad 
CA, USA), and the MDA-MB-231 cell line was cultured 
in DMEM (Euroclone, Pero MI, Italy); both media were 
supplemented with 10% fetal bovine serum (GIBCO, Life 
Technologies Corporation), 2 mM UltraGlutamine (Lonza, 
Basel, Switzerland) and 10 mM Hepes (Lonza). The 
median cell size from both cell lines was determined with 
a Coulter counter pipette (Scepter, Millipore, Billerica, 
MA, USA). The EpCAM density was determined using 
a flow cytometer (FACS ARIA II, BD Biosciences, San 
Jose, CA, USA) and QuantiBrite beads (BD Biosciences). 
The MDA-MB-231 cells and PC3 cells were spiked 
in healthy donor CellSave blood. Cell numbers for spiking 
were counted manually with a fluorescent microscope, 
using the nuclear dye Hoechst 33342 for visualization on 
a glass slide. Targeting a spike number of 250 cells in 7.5 
mL blood volume, the exact number of cells was counted 
before adding the cells to the blood and subsequently used 
to determine the recovery in the CellSearch and on the 
microsieve. On average, 270 cells were spiked per tube. 
Unspiked blood samples from healthy volunteers were 
used as a negative control. Spiked samples were prepared 
at the IOV laboratory and distributed under temperature 
control to the six sites to be processed after 48 hours. Each 
site received a tube of unspiked blood (labeled A), one 
tube spiked with PC3 cells (labeled B) and one tube spiked 
with MDA-MB231 cells (labeled C), all from one donor. 
This was repeated three times with three different donors.
CTC detection by CellSearch 
CTC were enumerated in aliquots of 7.5 mL of 
blood with the CellSearch® Circulating Tumor Cell Kit 
(Menarini Silicon Biosystems). Analysis was performed 
within 96 hours of the blood draw. Blood samples were 
enriched for EpCAMhigh cells and stained with DAPI, 
Cytokeratin-PE and CD45-APC on the CellTracks 
Autoprep. Image acquisition of the stained cartridges was 
performed on the CellTracks Analyzer II. Images of CTC 
candidates were identified by the CellTracks Analyzer II 
and presented to experienced operators for classification. 
Candidates were assigned as CTC when the objects were 
larger than 4 µm, stained with DAPI and CK, lacked 
CD45 staining and had morphological features consistent 
with that of a cell [1]. 
Blood sample collection after EpCAMhigh CTC 
enrichment
After immunomagnetic selection of EpCAMhigh cells, 
the CellTracks Autoprep aspirates the blood that is void 
of the selected cells and transports it to a waste container 
outside the instrument. To enable the investigation of this 
blood for residual tumor cells, the sample was collected 
manually or with the specific designed Automated Sample 
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Collection Device (ASCD), as described previously [9]. 
For manual collection of the Autoprep discarded blood 
sample, the top of the waste container was removed. After 
visual inspection of presence of blood in the tubing coming 
out of the Autoprep, a 50 mL conical tube is placed under 
the outlet and the sample is collected until no blood can 
be observed anymore in the tubing. This is repeated for 
each sample. The first blood arrives at the waste container 
approximately 1 hour after start of the Autoprep. The 
protocols and tools are described in more detail at https://
www.utwente.nl/tnw/mcbp/protocolsandtools/.
Filtration of the discarded CellTracks Autoprep 
blood sample
To filter tumor cells from the EpCAMhigh CTC 
depleted blood sample, microsieve membranes were used 
(VyCAP, Deventer, The Netherlands). Each microsieve 
contains 111,800 pores of 5 μm in diameter and these pores 
are spaced 14 μm apart in lanes with a porosity of 10% on 
a total surface area of 8 by 8 mm2. The specifications of 
the microsieves were obtained from previous experiments 
[9, 11, 26]. The microsieve is contained in a plastic holder 
that was placed in a disposable filtration unit, which can 
be placed on a pump unit that maintained a pressure of 
-100 mbar across a microsieve during filtration (VyCAP). 
The CellSearch discarded blood sample was transferred 
to the filtration unit after which the pump was switched 
on. The collected blood sample, varying between 25 to 40 
mL, was passed through in maximum 10 minutes. After 
complete filtration of the sample or after 10 minutes, the 
pump was switched off and if there was any unfiltered 
sample volume remaining, this was removed with a 
pipette. Details of the volumes that were not filtered were 
used to determine how much whole blood volume was 
processed.
Staining of cells on microsieves
Conditions for staining on microsieves were 
optimized to assure uniform staining across the microsieve 
with a minimum of non-specific binding. After filtration, 
the microsieve was removed and washed once with a 
permeabilization buffer containing PBS, 1% bovine serum 
albumin (Sigma-Aldrich, St. Louis MO, USA) and 0.15% 
saponin (Sigma-Aldrich). Next, this buffer was placed 
on the sieve and removed after 15 minutes incubation 
at room temperature. A cocktail of fluorescently labeled 
antibodies was used to stain the cells on the sieve for 15 
minutes at 37° C. The staining solution consisted of the 
following monoclonal antibodies: three CK antibody 
clones targeting CK 4, 5, 6, 8, 10, 13, 18 (clone C11), 
CK 1-8 (clone AE3) and CK 10, 14, 15, 16 and 19 (clone 
AE1), all conjugated to NTb575 (AcZon s.r.l., Bologna, 
Italy), and one antibody targeting CD45 (clone HI30) 
labelled with PerCP (Thermo Fisher Scientific, Waltham 
MA, USA). The CK-pan cocktail was diluted to a final 
concentration of 3.5 µg/mL and the anti-CD45 antibody 
was diluted to 4 µg/mL in PBS/1%BSA/0.05% saponin. 
After removal of the staining cocktail, the microsieve was 
washed once and then incubated for 5 minutes at room 
temperature with PBS/1%BSA. Then the sample was 
Table 2: Patient demographics
Castration-resistant prostate cancer 
patients n = 85 Metastatic breast cancer patients n = 16
Age (years) Age (years) 
Median (range) 71 (49–84) Median (range) 63 (37–89)
Unknown 24 (28%) Unknown 1 (6%)
Status at last follow-up Status at last follow-up
Alive 38 (45%) Alive 12 (75%)
Dead 47 (55%) Dead 4 (25%)
Mean follow-up time in months (min-max) Mean follow-up time in months (min-max)
Alive 13 (0–28) Alive 11 (3–17)
Dead 09 (0–27) Dead 4 (2–8)
Line of therapy Line of therapy
Before therapy 08 (9%) Before therapy 5 (31%)
1st line 10 (12%) 1st line 2 (13%)
2nd  line 19 (22%) 2nd  line 1 (6%)
≥3rd line 24 (28%) ≥ 3rd line 7 (44%)
Unknown 25 (29%) Unknown 1 (6%)
The demographics of the patients in this study with known clinical outcome.
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fixed using PBS with 1% formaldehyde (Sigma-Aldrich) 
for 10 minutes at room temperature. Removal of the fluid 
during each of the staining and washing steps was done 
by bringing the bottom of the microsieve in contact with 
an absorbing material using a staining holder (VyCAP). 
The microsieve was subsequently covered with ProLong® 
Diamond Antifade Mountant with DAPI (Thermo Fisher 
Scientific). A custom cut 0.85 × 0.85 cm2 glass cover slip 
(Menzel-Gläser, Saarbrükener, Germany) was placed on 
both sides of the microsieve for immediate analysis or 
storage in the freezer at −30° C.  
Detection of cells on microsieves
Microscopes at each site were equipped with a 20× 
microscope objective with minimal NA0.45 and the same 
set of filter cubes. The following filters were used: DAPI 
(DAPI-50LP-A-NQF) with excitation 377/50 nm, dichroic 
409 nm LP, emission 409 nm LP; PE (TRITC-B-NQF) 
with excitation 543/22 nm, dichroic 562 nm LP, emission 
593/40 nm and PerCP (FF02-435/40, FF510-Di02 and 
FF01-676/29 (customized filter cube)) with excitation 
435/40 nm, dichroic 510 nm LP, emission 676/29 nm. All 
cubes were acquired via Nikon (Semrock, Rochester, NY, 
USA). Images covering the entire 0.64 cm2 surface of the 
microsieves were acquired and stored. 
Scoring of CTC
Analysis of the fluorescent images generated from 
the CellSearch cartridges were performed according the 
instructions of the manufacturer. The fluorescent images 
from the microsieves were analyzed using the open-source 
software ICY [27]. Operators were asked to annotate 
every DAPI+/CK+/CD45– event. In case of clogging of 
the microsieve, CTC counts were extrapolated to the full 
volume. Images of CTC were analyzed for their intensity 
in CK, thereby deducting the background value from the 
intensity value of CK staining ranging from 0 to 4095 counts.
Statistical analysis
Statistical analysis was performed in R (version 
3.3.0) and SPSS (Statistics 24). For survival analysis, 
patients were divided in two prognostic groups: favorable 
for less than 5 CTC and unfavorable ≥5 CTC [2, 4]. 
Kaplan–Meier curves for overall survival were generated 
and compared using the Log-Rank test. A receiver 
operating characteristic curve was used to determine 
the EpCAMlow CTC threshold for the highest diagnostic 
ability. A p-value of < 0.05 was considered to indicate a 
significant difference.
Abbreviations
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